Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.785 USD | -11.85% | -28.88% | +39.45% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 18.63 | 90.32 | 45.98 | 23.07 | 25.89 | 116.9 | - | - |
Enterprise Value (EV) 1 | -0.8649 | 63.88 | 45.98 | -1.157 | 6.216 | 36.09 | 76.21 | 28.61 |
P/E ratio | -0.82 x | -3 x | -0.98 x | -0.74 x | -0.81 x | -2.93 x | -2.33 x | -2.25 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 2.73 x | 9.03 x | - | - | - | - | - | - |
EV / Revenue | -0.13 x | 6.38 x | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | -2,01,283 x | - | - | - |
EV / FCF | - | - | - | - | - | -0.9 x | -1.66 x | -0.43 x |
FCF Yield | - | - | - | - | - | -111% | -60.4% | -231% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 2,093 | 6,690 | 14,597 | 16,840 | 20,223 | 65,466 | - | - |
Reference price 2 | 8.900 | 13.50 | 3.150 | 1.370 | 1.280 | 1.785 | 1.785 | 1.785 |
Announcement Date | 12/03/20 | 09/03/21 | 10/03/22 | 23/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 6.832 | 10.01 | - | - | - | - | - | - |
EBITDA | - | - | - | - | -30.88 | - | - | - |
EBIT 1 | -16.83 | -14.16 | -27.82 | -28.24 | -31.11 | -37.01 | -51.67 | -66 |
Operating Margin | -246.4% | -141.47% | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -18.59 | -15.73 | -27.81 | -28.32 | -30.04 | -35.4 | -51.44 | -66 |
Net income 1 | -18.59 | -15.73 | -27.81 | -28.32 | -30.04 | -34.6 | -48.91 | -58.85 |
Net margin | -272.13% | -157.21% | - | - | - | - | - | - |
EPS 2 | -10.80 | -4.500 | -3.200 | -1.860 | -1.580 | -0.6100 | -0.7650 | -0.7950 |
Free Cash Flow 1 | - | - | - | - | - | -40 | -46 | -66 |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 12/03/20 | 09/03/21 | 10/03/22 | 23/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -6.96 | -6.569 | -7.175 | -7.563 | -6.932 | -7.369 | -7.315 | -8.125 | -8.3 | -8.826 | -8.6 | -9.767 | -9.767 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -7.133 | -6.718 | -7.258 | -7.551 | -6.795 | -7.139 | -7.012 | -7.824 | -8.061 | -8.469 | -8.24 | -9.083 | -9.423 | - | - |
Net income 1 | -7.133 | -6.719 | -7.258 | -7.551 | -6.795 | -7.139 | -7.013 | -7.824 | -8.061 | -8.469 | -8.13 | -8.788 | -9.068 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.7000 | -0.5000 | -0.5000 | -0.5000 | -0.4000 | -0.4200 | -0.3700 | -0.4000 | -0.4000 | -0.2900 | -0.1240 | -0.1340 | -0.1360 | -0.1850 | -0.1850 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 23/03/23 | 11/05/23 | 08/08/23 | 09/11/23 | 21/03/24 | 09/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 19.5 | 26.4 | - | 24.2 | 19.7 | 80.8 | 40.7 | 88.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | - | - | -40 | -46 | -66 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.36 | - | 1 | 0.85 | 0.9 |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 12/03/20 | 09/03/21 | 10/03/22 | 23/03/23 | 21/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.45% | 12Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- RGLS Stock
- Financials Regulus Therapeutics Inc.